Aeolus Pharmaceuticals Inc.
23811 Inverness Place
Laguna Niguel
California
92677
United States
Tel: 949-481-9825
Fax: 949-481-9829
Website: http://www.aeoluspharma.com/
127 articles about Aeolus Pharmaceuticals Inc.
-
Aeolus Pharmaceuticals Inc. Announces Fiscal Year 2016 Financial Results
12/21/2016
-
Aeolus Pharmaceuticals Inc. Announces First Quarter Fiscal Year 2016 Financial Results
2/17/2016
-
Aeolus Pharmaceuticals Inc. Announces Complete Results From Successful Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused By Acute Radiation Exposure
5/4/2015
-
Aeolus Pharmaceuticals Inc. Receives Orphan Drug Designation From US FDA For AEOL 10150 For Treatment Of Idiopathic Pulmonary Fibrosis
3/17/2015
-
Aeolus Pharmaceuticals Inc. Files Investigational New Drug Application With U.S FDA To Enable Initiation Of Human Safety Studies For The Development Of AEOL 10150 As A Medical Countermeasure Against Lung Damage From Radiation Exposure
8/20/2014
-
Aeolus Pharmaceuticals Inc. Announces Third Quarter Fiscal Year 2014 Financial Results And Achievements In Lung-ARS Development Program
8/18/2014
-
Aeolus Pharmaceuticals Inc. Announces Additional Data Demonstrating Efficacy Of AEOL 10150 As A Medical Countermeasure Against Exposure To Nerve Agents, Sulfur Mustard Gas And Nitrogen Mustard Gas
7/1/2014
-
Aeolus Pharmaceuticals Inc. Announces Publication Of Data Demonstrating Efficacy Of AEOL 10150 In Animal CEES Model Of Mustard Gas Skin Exposure
6/18/2014
-
Aeolus Pharmaceuticals Inc. To Present At LD Micro Invitational Conference
6/3/2014
-
Aeolus Pharmaceuticals Inc. Announces Second Quarter Fiscal Year 2014 Financial Results And Achievements In Lung-ARS Development Program
5/16/2014
-
Aeolus Pharmaceuticals Inc. Announces First Quarter Fiscal Year 2014 Financial Results
2/17/2014
-
Aeolus Pharmaceuticals Inc. Announces Process Improvements And Positive 18 Month Stability Results For AEOL 10150 In New Formulation
2/13/2014
-
Aeolus Pharmaceuticals Inc. Announces Publication Of Data Demonstrating Efficacy Of AEOL 10150 In Animal Model Of Lung Radiation Exposure; Models Developed For Pivotal Efficacy Studies
2/11/2014
-
Aeolus Pharmaceuticals Inc. Receives Orphan Drug Designation For AEOL 10150 From U.S. FDA
1/23/2014
-
Aeolus Pharmaceuticals Inc. Announces Fiscal Year 2013 Financial Results
12/27/2013
-
Aeolus Pharmaceuticals Inc. Files Application For New Patent On AEOL 10150
12/5/2013
-
Aeolus Pharmaceuticals Inc.' AEOl 10150 Significantly Improves Survival and Protects Lungs in Mice Exposed to Lethal Radiation
10/29/2013
-
Biomedical Advanced Research and Development Authority (BARDA) Exercises $6 Million in Additional Contract Funding for Development of AEOL-10150 as Treatment for Acute Radiation Syndrome
9/18/2013
-
Aeolus Pharmaceuticals Inc.' AEOL 10150 Significantly Improves Survival From Nitrogen Mustard Exposure to Skin in Animals
7/2/2013
-
Aeolus Pharmaceuticals Inc.'s AEOL 10150 Significantly Improves Survival in Animals Exposed to Mustard Gas
6/26/2013